维多珠单抗在治疗难治性免疫检查点抑制剂诱导的肠炎中的新作用。
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.
作者信息
Diana Pietro, Mankongpaisarnrung Charoen, Atkins Michael B, Zeck Jay C, Charabaty Aline
机构信息
Vita-Salute San Raffaele University, Milan, Italy.
Sanford School of Medicine, University of South Dakota, Sioux Falls, SD.
出版信息
ACG Case Rep J. 2018 Feb 28;5:e17. doi: 10.14309/crj.2018.17. eCollection 2018.
We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down steroids. Vedolizumab's mechanism of action and its gut specificity have the potential to reverse immune-induced enterocolitis without neutralizing or reversing the therapeutic benefit of ICI on the malignancy.
我们报告了一名62岁的白人女性，患有转移性脉络膜黑色素瘤，她发生了免疫检查点抑制剂（ICI）诱导的肠炎以及对类固醇和英夫利昔单抗难治的3级腹泻。在输注维多珠单抗后，她的腹泻迅速缓解，患者能够逐渐减少类固醇用量。维多珠单抗的作用机制及其肠道特异性有可能逆转免疫诱导的小肠结肠炎，而不会中和或逆转ICI对恶性肿瘤的治疗益处。
Zotero 插件